Key factors
symLLY
exchUS
MCap709.22B
Beta0.367
PE Ratio129.05
EPS5.78
Div4.52
Div Yld0.689
Div date2024-02-14
Yesterday
symLLY
exchUS
close733.51
50 Day MA762.23
200 Day MA614.20
52 Week High800.78
52 Week Low367.60
Target Price 826.94
Market Cap Mln709.22K
Share statistics
Shares Outstanding950.76M
Shares Float897.84M
Percent Institutions84.31
PercentInsiders0.163
SharesShort5420.67K
Short Ratio1.82
Shares Short Prior Month5423.38K
Short Percent0.639
Revenue TTM 34.12B
Revenue Per Share TTM 37.90
Quarterly Revenue Growth YOY 28.09
Gross Profit TTM 21.91B
EBITDA12.31B
Diluted Eps TTM5.78
Quarterly Earnings Growth YOY12.99
earning
Operating Margin TTM 0.341
PEGRatio 1.431
Trailing PE 129.05
EPS Estimate Current Quarter 2.22
EPS Estimate Current Year 12.5
EPS Estimate Next Quarter 2.61
EPS Estimate Next Year 18.22
Earnings Share 5.78
Dividend
Forward Annual Dividend Rate 5.2
Forward Annual Dividend Yield 0.689
Payout Ratio 74.21
Dividend Date2024-03-08
Last Split Date 1997-10-16
Last Split Factor2:1
business
Enterprise Value Ebitda 86.01
Enterprise Value Revenue21.59
Book Value /share 11.97
Price Book MRQ 66.34
Price Sales TTM 20.94
ProfitMargin 0.153
ReturnOnAssetsTTM 0.118
ReturnOnEquityTTM0.484
Gic GroupPharmaceuticals, Biotechnology & Life Sciences
Gic IndustryPharmaceuticals
Gic Sector Health Care
Gic Sub Industry Pharmaceuticals
IndustryDrug Manufacturers - General
SectorHealthcare
ISIN US5324571083
CIK 59478
Code LLY
CUSIP 532457108
Employer Id Number 35-0470950
CountryISO US
Currency CodeUSD
Currency Name US Dollar
Exchange NYSE
Currency Symbol $
Type Common Stock
UpdatedAt 2024-04-19
Home Category Domestic Primary
Fiscal Year End December
ForwardPE 60.24
Full Time Employees43000
IPODate 1978-01-13
International Domestic International Domestic
MostRecent Quarter2023-12-31
Contact
NameEli Lilly and Company
AddressLilly Corporate Center, Indianapolis, IN, United States, 46285
Country NameUSA
Phone317 276 2000
Web URLhttps://www.lilly.com
Logo URL/img/logos/US/LLY.png
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.